Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
7 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Development of an intravitreal peptide (BQ123) sustained release system based on poly(2-hydroxyoctanoic acid) aiming at a retinal vasodilator response.
J Ocul Pharmacol Ther. 2014 Aug;30(6):517-23. doi: 10.1089/jop.2013.0117. Epub 2014 May 19.
J Ocul Pharmacol Ther. 2014.
PMID: 24978907
Design and in vitro assessment of L-lactic acid-based copolymers as prodrug and carrier for intravitreal sustained L-lactate release to reverse retinal arteriolar occlusions.
Veurink M, Asmus L, Hennig M, Kaufmann B, Bagnewski L, Heiligenhaus A, Mendrinos E, Pournaras CJ, Gurny R, Möller M.
Veurink M, et al.
Eur J Pharm Sci. 2013 May 13;49(2):233-40. doi: 10.1016/j.ejps.2013.02.021. Epub 2013 Mar 14.
Eur J Pharm Sci. 2013.
PMID: 23500039
Item in Clipboard
Association of ranibizumab (Lucentis®) or bevacizumab (Avastin®) with dexamethasone and triamcinolone acetonide: an in vitro stability assessment.
Veurink M, Stella C, Tabatabay C, Pournaras CJ, Gurny R.
Veurink M, et al.
Eur J Pharm Biopharm. 2011 Jun;78(2):271-7. doi: 10.1016/j.ejpb.2010.12.018. Epub 2010 Dec 21.
Eur J Pharm Biopharm. 2011.
PMID: 21172437
Item in Clipboard
Breaking the aggregation of the monoclonal antibody bevacizumab (avastin®) by dexamethasone phosphate: insights from molecular modelling and asymmetrical flow field-flow fractionation.
Veurink M, Westermaier Y, Gurny R, Scapozza L.
Veurink M, et al.
Pharm Res. 2013 Apr;30(4):1176-87. doi: 10.1007/s11095-012-0955-6. Epub 2013 Feb 15.
Pharm Res. 2013.
PMID: 23412914
Item in Clipboard
Identification of aggregation breakers for bevacizumab (Avastin®) self-association through similarity searching and interaction studies.
Westermaier Y, Veurink M, Riis-Johannessen T, Guinchard S, Gurny R, Scapozza L.
Westermaier Y, et al. Among authors: veurink m.
Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):773-80. doi: 10.1016/j.ejpb.2013.04.012. Epub 2013 May 9.
Eur J Pharm Biopharm. 2013.
PMID: 23665445
Item in Clipboard
Low essential fatty acid and B-vitamin status in a subgroup of patients with schizophrenia and its response to dietary supplementation.
Kemperman RF, Veurink M, van der Wal T, Knegtering H, Bruggeman R, Fokkema MR, Kema IP, Korf J, Muskiet FA.
Kemperman RF, et al. Among authors: veurink m.
Prostaglandins Leukot Essent Fatty Acids. 2006 Feb;74(2):75-85. doi: 10.1016/j.plefa.2005.11.004. Epub 2005 Dec 27.
Prostaglandins Leukot Essent Fatty Acids. 2006.
PMID: 16384692
Clinical Trial.
Item in Clipboard
The history of DES, lessons to be learned.
Veurink M, Koster M, Berg LT.
Veurink M, et al.
Pharm World Sci. 2005 Jun;27(3):139-43. doi: 10.1007/s11096-005-3663-z.
Pharm World Sci. 2005.
PMID: 16096877
Review.
Item in Clipboard
Cite
Cite